Naperville, IL -- (SBWIRE) -- 08/08/2014 -- Reportstack, provider of premium market research reports announces the addition of Global Hodgkins Lymphoma Therapeutics Market 2014-2018 market report to its offering
About Hodgkin's Lymphoma
Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infection-fighting properties of the lymphocytes are lost, making the person more susceptible to infection. The main treatments used are chemotherapy, followed by radiotherapy or chemotherapy alone. Generally surgery is not used as a treatment for the condition.
Analysts forecast the Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018.
Covered in this Report
The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.
Global Hodgkin's Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hodgkin's Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
Americas
APAC
EMEA
Key Vendors
Bristol Myers Squibb Co.
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Pfizer Inc.
Other Prominent Vendors
4SC AG
Actinium Pharmaceuticals Inc.
Aeterna Zentaris Inc.
Affimed Therapeutics AG
Hospira Inc.
Incyte Corp.
Novartis AG
Philogen S.p.A.
Seattle Genetics Inc.
Sigma-Tau Pharmaceuticals Inc.
Stemline Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.
Key Market Driver
Improved Diagnostic Techniques.
For a full, detailed list, view our report.
Key Market Challenge
High Cost.
For a full, detailed list, view our report.
Key Market Trend
Increase in Awareness of HL.
For a full, detailed list, view our report.
Key Questions Answered in this Report
What will the market size be in 2018 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Companies Mentioned
Bristol Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc. , 4SC AG, Actinium Pharmaceuticals Inc., Aeterna Zentaris Inc., Affimed Therapeutics AG, Hospira Inc., Incyte Corp., Novartis AG, Philogen S.p.A., Seattle Genetics Inc., SigmaTau Pharmaceuticals Inc., Stemline Therapeutics Inc., Teva Pharmaceutical Industries Ltd
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/166176/global-hodgkins-lymphoma-therapeutics-market-2014-2018.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604